Provectus Biopharmaceuticals (OTCMKTS:PVCT), Signs Exclusive License Option Agreement Institute at University of Miami for Treating Eye Infections

September 22, 2022

Provectus Biopharmaceuticals (OTCMKTS:PVCT), on September 21, 2022, announced about entering into an option agreement with the University of Miami (UM) for an exclusive worldwide license of intellectual property developed by the Ophthalmic Biophysics Center (OBC) of Bascom Palmer Eye Institute (BPEI), part of the UM Health System. Trading Data On Wednesday, PVCT stock moved up 4.25% to $0.0540 with more than 506.72K shares, compared to its average volume of 177.09K…

Read More >>

Provectus Biopharmaceuticals (OTCMKTS:PVCT) Expands Sponsored Research Programs

August 25, 2022

Provectus Biopharmaceuticals Inc (OTCMKTS:PVCT) made an announcement on August 24, 2022, that it has expanded its sponsored research program with Michio Kurosu, PhD, Professor, Department of Pharmaceutical Sciences at the College of Pharmacy of the University of Tennessee Health Science Center (UTHSC) in Memphis, Tennessee. Trading Data            On Wednesday, PVCT stock fell 3.86% to $0.0510 with more than 508.01K shares, compared to volume of 153.82K shares. The stock moved within…

Read More >>